Alliancebernstein L.P. Has $231.98 Million Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Alliancebernstein L.P. lifted its position in Axon Enterprise, Inc. (NASDAQ:AXONGet Rating) by 11.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,477,546 shares of the biotechnology company’s stock after acquiring an additional 149,915 shares during the period. Alliancebernstein L.P.’s holdings in Axon Enterprise were worth $231,975,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of AXON. American Century Companies Inc. raised its stake in shares of Axon Enterprise by 4.8% in the third quarter. American Century Companies Inc. now owns 6,179 shares of the biotechnology company’s stock valued at $1,081,000 after purchasing an additional 281 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Axon Enterprise in the third quarter valued at $236,000. Oppenheimer Asset Management Inc. raised its stake in shares of Axon Enterprise by 13.8% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,494 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 181 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Axon Enterprise in the third quarter valued at $476,000. Finally, Credit Suisse AG raised its stake in Axon Enterprise by 11.3% during the third quarter. Credit Suisse AG now owns 101,116 shares of the biotechnology company’s stock worth $17,698,000 after acquiring an additional 10,279 shares in the last quarter. Institutional investors and hedge funds own 72.06% of the company’s stock.

In related news, CFO Jawad A. Ahsan sold 4,840 shares of the firm’s stock in a transaction dated Tuesday, April 5th. The stock was sold at an average price of $141.17, for a total value of $683,262.80. Following the transaction, the chief financial officer now owns 360,019 shares in the company, valued at $50,823,882.23. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.

Axon Enterprise stock opened at $102.52 on Friday. The business’s 50-day simple moving average is $116.23 and its 200 day simple moving average is $136.00. The stock has a market cap of $7.28 billion, a price-to-earnings ratio of 197.16 and a beta of 0.55. Axon Enterprise, Inc. has a 12-month low of $82.49 and a 12-month high of $209.00. The company has a quick ratio of 2.18, a current ratio of 2.43 and a debt-to-equity ratio of 0.02.

Axon Enterprise (NASDAQ:AXONGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.16. The business had revenue of $256.43 million for the quarter, compared to analysts’ expectations of $233.57 million. Axon Enterprise had a return on equity of 3.90% and a net margin of 4.62%. The firm’s quarterly revenue was up 31.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.75) earnings per share. As a group, sell-side analysts expect that Axon Enterprise, Inc. will post 1.35 EPS for the current year.

AXON has been the subject of several recent analyst reports. Needham & Company LLC dropped their price objective on Axon Enterprise from $250.00 to $170.00 and set a “buy” rating for the company in a research note on Friday, February 25th. Northland Securities dropped their price objective on Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. JPMorgan Chase & Co. upgraded Axon Enterprise from a “neutral” rating to an “overweight” rating and dropped their price objective for the stock from $222.00 to $192.00 in a research note on Friday, February 25th. Zacks Investment Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 19th. Finally, Morgan Stanley cut Axon Enterprise from an “overweight” rating to an “equal weight” rating and set a $120.00 target price on the stock. in a report on Monday, May 23rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $165.60.

About Axon Enterprise (Get Rating)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

See Also

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXONGet Rating).

Institutional Ownership by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.